Literature DB >> 8172944

Apolipoprotein E-4 gene dose in clinically diagnosed Alzheimer's disease: prevalence, plasma cholesterol levels and cerebrovascular change.

C Czech1, H Förstl, F Hentschel, U Mönning, C Besthorn, C Geiger-Kabisch, H Sattel, C Masters, K Beyreuther.   

Abstract

The prevalence of the apolipoprotein E-4 allele (ApoE-4) was significantly higher in a referral population of 40 patients with clinically diagnosed Alzheimer's disease than in a sample of non-demented elderly controls (P < 0.01). The highest plasma cholesterol levels were found in demented patients homozygotic for Apo E-4, but no significant increases of glucose, triglycerides and thyroxine or of leuko-araiosis and brain infarcts were verified in this preliminary study.

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 8172944     DOI： 10.1007/bf02191587

Source DB:  PubMed          Journal:  Eur Arch Psychiatry Clin Neurosci        ISSN： 0940-1334            Impact factor:   5.270


  10 in total

1.  Apolipoprotein E genotyping by one-stage PCR.

Authors:  P R Wenham; W H Price; G Blandell
Journal:  Lancet       Date:  1991-05-11       Impact factor: 79.321

2.  Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI.

Authors:  J E Hixson; D T Vernier
Journal:  J Lipid Res       Date:  1990-03       Impact factor: 5.922

3.  Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families.

Authors:  E H Corder; A M Saunders; W J Strittmatter; D E Schmechel; P C Gaskell; G W Small; A D Roses; J L Haines; M A Pericak-Vance
Journal:  Science       Date:  1993-08-13       Impact factor: 47.728

4.  Apolipoprotein E and Alzheimer's disease.

Authors:  J Scott
Journal:  Lancet       Date:  1993-09-18       Impact factor: 79.321

5.  Apolipoprotein E polymorphism and Alzheimer's disease.

Authors:  J Poirier; J Davignon; D Bouthillier; S Kogan; P Bertrand; S Gauthier
Journal:  Lancet       Date:  1993-09-18       Impact factor: 79.321

6.  Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease.

Authors:  G McKhann; D Drachman; M Folstein; R Katzman; D Price; E M Stadlan
Journal:  Neurology       Date:  1984-07       Impact factor: 9.910

7.  Modulation of plasma triglyceride levels by apoE phenotype: a meta-analysis.

Authors:  J Dallongeville; S Lussier-Cacan; J Davignon
Journal:  J Lipid Res       Date:  1992-04       Impact factor: 5.922

8.  Psychotic features and the course of Alzheimer's disease: relationship to cognitive, electroencephalographic and computerized tomography findings.

Authors:  H Förstl; C Besthorn; C Geiger-Kabisch; H Sattel; U Schreiter-Gasser
Journal:  Acta Psychiatr Scand       Date:  1993-06       Impact factor: 6.392

Review 9.  Apolipoprotein E polymorphism and atherosclerosis.

Authors:  J Davignon; R E Gregg; C F Sing
Journal:  Arteriosclerosis       Date:  1988 Jan-Feb

10.  Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease.

Authors:  W J Strittmatter; A M Saunders; D Schmechel; M Pericak-Vance; J Enghild; G S Salvesen; A D Roses
Journal:  Proc Natl Acad Sci U S A       Date:  1993-03-01       Impact factor: 11.205
  10 in total
  7 in total

Review 1.  The role of gonadotropins in Alzheimer's disease: potential neurodegenerative mechanisms.

Authors:  Anna M Barron; Giuseppe Verdile; Ralph N Martins
Journal:  Endocrine       Date:  2006-04       Impact factor: 3.633

Review 2.  LXR agonists: new potential therapeutic drug for neurodegenerative diseases.

Authors:  Pei Xu; Dabing Li; Xiaotong Tang; Xiaohang Bao; Jing Huang; Yongping Tang; Yang Yang; Haiwei Xu; Xiaotang Fan
Journal:  Mol Neurobiol       Date:  2013-04-27       Impact factor: 5.590

3.  Plastic neuronal remodeling is impaired in patients with Alzheimer's disease carrying apolipoprotein epsilon 4 allele.

Authors:  T Arendt; C Schindler; M K Brückner; K Eschrich; V Bigl; D Zedlick; L Marcova
Journal:  J Neurosci       Date:  1997-01-15       Impact factor: 6.167

4.  On cholesterol levels and statins in cognitive decline and Alzheimer disease: progress and setbacks.

Authors:  Marwan N Sabbagh; Kabir Thind; David Larry Sparks
Journal:  Alzheimer Dis Assoc Disord       Date:  2009 Oct-Dec       Impact factor: 2.703

5.  The number of cysteine residues per mole in apolipoprotein E affects systematically synchronous neural interactions in women's healthy brains.

Authors:  Arthur C Leuthold; Margaret Y Mahan; John J Stanwyck; Angeliki Georgopoulos; Apostolos P Georgopoulos
Journal:  Exp Brain Res       Date:  2013-03-17       Impact factor: 1.972

6.  Should the guidelines for monitoring serum cholesterol levels in the elderly be re-evaluated?

Authors:  D Larry Sparks; Donald J Connor; Patrick Browne; Marwan N Sabbagh
Journal:  J Mol Neurosci       Date:  2002 Aug-Oct       Impact factor: 3.444

7.  APOEɛ4 Gene Dose and Sex Effects on Alzheimer's Disease MRI Biomarkers in Older Adults with Mild Cognitive Impairment.

Authors:  Zachary Hobel; A Lisette Isenberg; Dhvani Raghupathy; Wendy Mack; Judy Pa
Journal:  J Alzheimers Dis       Date:  2019       Impact factor: 4.472
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.